Merck and Moderna Report Promising Phase 3 Melanoma Data

Rahway, New Jersey, and Cambridge, Massachusetts, United States, October 22, 2026

Phase 3 Trial Shows Reduced Risk of Melanoma Recurrence

In the primary prespecified analysis, patients receiving intismeran autogene alongside KEYTRUDA experienced a 42% reduction in the risk of recurrence or death compared with those receiving KEYTRUDA alone. The result was based on a hazard ratio of 0.58, with a 95% confidence interval of 0.45–0.75 and a two-sided p-value below 0.001. The combination also reduced the risk of distant metastasis or death by 38%, with a hazard ratio of 0.62 (95% confidence interval 0.45–0.85; p=0.002). These findings were observed after a median follow-up of 24.6 months. The INTerpath-001 study enrolled 1,137 patients with high-risk, completely resected stage IIB, IIC, III, or IV cutaneous melanoma who had not previously received systemic treatment for their disease. Participants were randomized to receive intismeran autogene plus pembrolizumab or pembrolizumab alone in an adjuvant treatment setting following surgery. Overall survival data remain immature, and the study continues to evaluate this and other important outcomes. The findings therefore demonstrate improvements in recurrence-related endpoints, rather than establishing a confirmed overall-survival benefit.

Personalized mRNA Therapy Targets Tumor-Specific Mutations

Intismeran autogene is an individualized mRNA-based neoantigen therapy designed around the unique mutation profile of an individual patient’s tumor. Following tumor analysis, the treatment is developed to encode selected tumor-specific neoantigens, with the goal of training and activating the immune system to recognize and attack cancer cells. KEYTRUDA, Merck’s anti-PD-1 immunotherapy, works through a complementary mechanism by blocking the PD-1 pathway, helping restore immune activity against cancer. Combining the two approaches is intended to support a more targeted immune response while maintaining the established immunotherapy component of treatment. The trial’s findings support further investigation of personalized cancer vaccines in the adjuvant setting, where treatment is given after surgery to reduce the risk of disease returning. The approach may offer a way to tailor treatment to the molecular characteristics of each patient’s cancer, although its ultimate clinical role will depend on additional evidence and regulatory review.

Safety Findings and Regulatory Next Steps

According to Merck and Moderna, the safety profile of intismeran autogene combined with KEYTRUDA was generally consistent with previously reported studies of the combination, and no new safety signals were observed in the Phase 3 trial. Continued monitoring remains important as the study progresses and additional follow-up data become available. The companies are engaging with regulatory authorities regarding the findings. However, intismeran autogene is investigational and is not yet an approved treatment for melanoma. Regulatory submissions, review, and any potential authorization will depend on the full evidence package and applicable agency decisions. The results build on earlier studies of the combination and form part of a broader clinical development program exploring individualized neoantigen therapies across several cancer types. Merck and Moderna are evaluating the approach in additional clinical studies involving melanoma and other solid tumors. For the biopharmaceutical industry, INTerpath-001 highlights growing interest in personalized immuno-oncology and the potential of combining mRNA-based therapies with checkpoint inhibitors. The ongoing study will help determine whether the observed improvements in recurrence-related outcomes translate into longer-term patient benefits.

Source: Merck, Moderna press release